Showing results (11-20 of 42) with videos related to
Sort By:
Pageof 5
American Journal of Physiology. Endocrinology and Metabolism|June 15, 2007
Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese malesBirgitte Sloth, Louise Davidsen, Jens Juul Holst, et al.The American Journal of Clinical Nutrition|December 25, 2002
Meals with similar energy densities but rich in protein, fat, carbohydrate, or alcohol have different effects on energy expenditure and substrate metabolism but not on appetite and energy intakeAnne Raben, Lisa Agerholm-Larsen, Anne Flint, et al.Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition Et Metabolisme|March 3, 2007
Contraction-mediated glucose uptake is increased in men with impaired glucose toleranceCamilla Skov-Jensen, Mette Skovbro, Anne Flint, et al.Diabetologia|May 21, 2017
Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trialChristoph Kapitza, Kirsten Dahl, Jacob B Jacobsen, et al.Advances in Therapy|March 15, 2018
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian SubjectsIppei Ikushima, Lene Jensen, Anne Flint, et al.American Journal of Physiology. Endocrinology and Metabolism|December 7, 2006
Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjectsBirgitte Sloth, Jens Juul Holst, Anne Flint, et al.Journal of Clinical Pharmacology|December 6, 2014
Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrelChristoph Kapitza, Leszek Nosek, Lene Jensen, et al.Clinical Pharmacokinetics|March 29, 2017
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal ImpairmentThomas C Marbury, Anne Flint, Jacob B Jacobsen, et al.Diabetes, Obesity & Metabolism|May 12, 2018
Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetesKristin C C Petri, Steen H Ingwersen, Anne Flint, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 17, 2018
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic AnalysisKristin Cecilie Carlsson Petri, Steen Hvass Ingwersen, Anne Flint, et al.Pageof 5